BGJ398 is an investigational drug.
There have been 22 clinical trials for BGJ398.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 27th 2019.
The most common disease conditions in clinical trials are Neoplasms, Carcinoma, and Cholangiocarcinoma. The leading clinical trial sponsors are Novartis Pharmaceuticals, National Cancer Institute (NCI), and Helsinn Healthcare SA.
There are one hundred and twenty-two US patents protecting this investigational drug and one international patent.